SHPG - Shire plc
| Previous Close | 169.72 |
| Open | 169.86 |
| Bid | 168.79 x 900 |
| Ask | 168.84 x 800 |
| Day's Range | 168.76 - 170.03 |
| 52 Week Range | 123.73 - 177.51 |
| Volume | 331,445 |
| Avg. Volume | 883,554 |
| Market Cap | 53.726B |
| Beta | 1.42 |
| PE Ratio (TTM) | 11.57 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.05 (0.61%) |
| Ex-Dividend Date | 2018-03-08 |
| 1y Target Est | N/A |
Yahoo Finance Video•21 days agoNYSE trader: Amazon, Visa and Twitter earnings are on my radar—their charts are very similar
Jonathan Corpina of Meridian Equity Partners joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest moves.
Yahoo Finance Video•2 months agoNike, Spotify and Shire are the Yahoo Finance charts of the day.
Let's check out the Yahoo Finance charts of the day. Nike (NKE): Shares are down in early trade, at around .22%. Nike was downgraded to "neutral" from "buy" with UBS saying it has a long-term bullish view on the athletic footwear and apparel maker. UBS also stated that the market has a similar view and the upbeat outlook is already priced into the stock. Spotify (SPOT): Shares up here, around 2.44%. In new coverage, Macquarie starts the music streaming service at "outperform" saying the evolution of the mobile digital market positions Spotify for years of growth. Shire (SHPG): Shares up here, at around .75%. The rare disease expert revealed that the FDA granted approval to make its Cinryze (SIN-RISE) drug available to children aged six and over. The drug has been approved for use by adults in the U.S. since 2008. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
- Zacks•yesterday
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
- Zacks•yesterday
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
- Thomson Reuters StreetEvents•8 days ago
Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT
Q2 2018 Shire PLC Earnings Call
- Zacks•13 days ago
Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.
- Associated Press•14 days ago
Shire: 2Q Earnings Snapshot
The Dublin-based company said it had net income of $2.01 per share. Earnings, adjusted for one-time gains and costs, were $3.88 per share. The results beat Wall Street expectations. The average estimate ...
Reuters•14 days agoShire profit edges higher ahead of Takeda sale
Shire (SHP.L), the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations. Earlier on Tuesday, Takeda said its first-quarter operating profit had halved from a year ago, when it had booked gains from asset sales. It is buying Shire to broaden its drugs portfolio and plug a gap in its late-stage pipeline.
- American City Business Journals•last month
U.S. regulator backs Takeda's $62B acquisition of Shire
In a statement, Takeda said the Federal Trade Commission's approval "is another significant milestone" for the $62 billion deal.
Reuters•last monthJapan's Takeda gains U.S. approval for $62 billion Shire buy
Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc (SHP.L), taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.
Reuters•last monthJapan's Takeda gains U.S. approval for $62 billion Shire buy
Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.
- Zacks•last month
Is Shire (SHPG) a Great Stock for Value Investors?
Let's put Shire (SHPG) stock into this equation and find out if it is a good choice for value-oriented investors right now.
- Bloomberg•last month
New Takeda HQ Flaunts Global Ambition Alongside Japan Roots
Embedded in the sleek metallic and cypress interior of Takeda Pharmaceutical Co.’s new global headquarters in Tokyo are stylized Japanese characters for words like life, water and light. Melding futuristic design with traditional Japanese elements highlights the balancing act facing Chief Executive Officer Christophe Weber: showing he can honor the 237-year-old drugmaker’s Japanese heritage as he tries to complete the biggest deal in Takeda’s history -- the $62 billion takeover of Shire Plc. “He’s very quick to say they’re still a Japanese company, but at the same time making a point to say they’re not Japanese because they have a very international, global executive team,” said John W. Carlson, chair of the health-care committee at the American Chamber of Commerce in Japan.
Reuters•2 months agoTakeda shareholders bin proposal from anti-Shire group; only 10 percent in favour
A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favour, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.
Reuters•2 months agoTakeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favor, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.
- American City Business Journals•2 months ago
FDA approves $1.2B plasma manufacturing center near Covington
An Irish company has received initial FDA approval for its $1.2 billion plasma manufacturing facility near Covington to produce an immunodeficiency treatment.
- Zacks•2 months ago
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.
- Yahoo Finance•2 months ago
Nike takes a dive, Spotify surges, Shire up slightly
Nike, Spotify and Shire are the Yahoo Finance charts of the day.
- Zacks•2 months ago
5 Biotech Stocks Under $10 Worthy of Investors' Attention
Small biotech stocks are good bets with lower market cap as well as share price.
